Understand the source comparison
Comparison: Bryan Johnson's Peptide Protocol vs Standard Research Approaches
Epithalon 10mg daily × 10–20 days 5–10mg daily × 10 days Every 3–6 months Subcutaneous injection Johnson's higher dose and extended cycle length exceed published study protocols. Likely based on private biomarker tracking rather than published guidelines BPC-1
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Epithalon
- 10mg daily × 10–20 days
- 5–10mg daily × 10 days
- Every 3–6 months
- Subcutaneous injection
- Johnson's higher dose and extended cycle length exceed published study protocols. Likely based on private biomarker tracking rather than published guidelines
- BPC-157
- 250–500mcg daily × 4–6 weeks
- 200–400mcg daily × 28 days
- As needed for injury recovery
- Subcutaneous near injury site
- Dosing aligns with rodent-to-human conversion factors; site-specific injection matches preclinical mechanistic studies
- Thymalin
- 10mg daily × 10 days
- Every 3 months
- Protocol matches Russian clinical studies from the 1990s; quarterly cycling reflects thymic involution timescale